Abstract
Lamotrigine has been used for patients with epilepsy and/or bipolar disorder, overdose of which induced the hypotension, elevation of the atrial pacing threshold, cardiac conduction delay, wide complex tachycardia, cardiac arrest and Brugada-like electrocardiographic pattern. To clarify how lamotrigine induces those cardiovascular adverse events, we simultaneously assessed its cardiohemodynamic and electrophysiological effects using the halothane-anesthetized dogs (n = 4). Lamotrigine was intravenously administered in doses of 0.1, 1 and 10 mg/kg/10 min under the monitoring of cardiovascular variables, possibly providing subtherapeutic to supratherapeutic plasma concentrations. The low or middle dose of lamotrigine did not alter any of the variables. The high dose significantly delayed the intra-atrial and intra-ventricular conductions in addition to the prolongation of ventricular effective refractory period, whereas no significant change was detected in the other variables. Lamotrigine by itself has relatively wide safety margin for cardiohemodynamics, indicating that clinically reported hypotension may not be induced through its direct action on the resistance arterioles or capacitance venules. The electrophysiological effects suggested that lamotrigine can inhibit Na+ channel in the in situ hearts. This finding may partly explain the onset mechanism of lamotrigine-associated cardiac adverse events in the clinical cases. In addition, elevation of J wave was induced in half of the animals, suggesting that lamotrigine may have some potential to unmask Brugada electrocardiographic genotype in susceptible patients.
Similar content being viewed by others
References
Alyahya B, Friesen M, Nauche B, Laliberté M (2018) Acute lamotrigine overdose: a systematic review of published adult and pediatric cases. Clin Toxicol 56:81–89
Irifune R, Matsuda M, Tagaya M, Hara K, Tamura R (2017) Marked elevation of the atrial pacing threshold in a patient with sinus dysfunction on lamotrigine therapy. Open J Clin Med Case Rep 3:1299
Strimel WJ, Woodruff A, Cheung P, Kirmani BF, Stephen Huang SK (2010) Brugada-like electrocardiographic pattern induced by lamotrigine toxicity. Clin Neuropharmacol 33:265–267
Rodrigues R, Amador P, Rassi L, Seixo F, Parreira L, Fonseca N, Soares L (2013) Brugada pattern in a patient medicated with lamotrigine (article in Portuguese; title and abstract were also provided in English). Rev Port Cardiol 32:807–810
Leong KMW, Seligman H, Varnava AM (2017) Proarrhythmogenic effects of lamotrigine during ajmaline testing for Brugada syndrome. HeartRhythm Case Rep 3:167–171
Lang DG, Wang CM, Cooper BR (1993) Lamotrigine, phenytoin and carbamazepine interactions on the sodium current present in N4TG1 mouse neuroblastoma cells. J Pharmacol Exp Ther 266:829–835
Xie X, Lancaster B, Peakman T, Garthwaite J (1995) Interaction of the antiepileptic drug lamotrigine with recombinant rat brain type IIA Na+ channels and with native Na+ channels in rat hippocampal neurons. Pflügers Arch 430:437–446
Zona C, Avoli M (1997) Lamotrigine reduces voltage-gated sodium currents in rat central neurons in culture. Epilepsia 38:522–525
Hainsworth AH, McNaughton NCL, Pereverzev A, Schneider T, Randall A (2003) Actions of sipatrigine, 202W92 and lamotrigine on R-type and T-type Ca2+ channel currents. Eur J Pharmacol 467:77–80
Polak S, Wisniowska B, Brandys J (2009) Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs’ cardiotoxic properties. J Appl Toxicol 29:183–206
Sugiyama A (2008) Sensitive and reliable proarrhythmia in vivo animal models for predicting drug-induced torsades de pointes in patients with remodelled hearts. Br J Pharmacol 154:1528–1537
Haïssaguerre M, Derval N, Sacher F, Jesel L, Deisenhofer I, de Roy L, Pasquié JL, Nogami A, Babuty D, Yli-Mayry S, De Chillou C, Scanu P, Mabo P, Matsuo S, Probst V, Le Scouarnec S, Defaye P, Schlaepfer J, Rostock T, Lacroix D, Lamaison D, Lavergne T, Aizawa Y, Englund A, Anselme F, O’Neill M, Hocini M, Lim KT, Knecht S, Veenhuyzen GD, Bordachar P, Chauvin M, Jais P, Coureau G, Chene G, Klein GJ, Clémenty J (2008) Sudden cardiac arrest associated with early repolarization. N Engl J Med 358:2016–2023
Yamazaki-Hashimoto Y, Nakamura Y, Ohara H, Cao X, Kitahara K, Izumi-Nakaseko H, Ando K, Yamazaki H, Ikeda T, Yamazaki J, Sugiyama A (2015) Fluvoxamine by itself has potential to directly induce long QT syndrome at supra-therapeutic concentrations. J Toxicol Sci 40:33–42
Van de Water A, Verheyen J, Xhonneux R, Reneman RS (1989) An improved method to correct the QT interval of the electrocardiogram for changes in heart rate. J Pharmacol Methods 22:207–217
Sugiyama A, Hashimoto K (1998) Effects of gastrointestinal prokinetic agents, TKS159 and cisapride, on the in situ canine heart assessed by cardiohemodynamic and electrophysiological monitoring. Toxicol Appl Pharmacol 152:261–269
Takahara A, Wagatsuma H, Aritomi S, Konda T, Akie Y, Nakamura Y, Sugiyama A (2011) Measurements of cardiac ion channel subunits in the chronic atrioventricular block dog. J Pharmacol Sci 116:132–135
Ishizue N, Niwano S, Saito M, Fukaya H, Nakamura H, Igarashi T, Fujiishi T, Yoshizawa T, Oikawa J, Satoh A, Kishihara J, Murakami M, Niwano H, Miyaoka H, Ako J (2016) Polytherapy with sodium channel-blocking antiepileptic drugs is associated with arrhythmogenic ST-T abnormality in patients with epilepsy. Seizure 40:81–87
Acknowledgements
This study was supported in part by JSPS KAKENHI (Grant Numbers 19K16505 and 20K16136). The authors thank Mrs. Yuri Ichikawa for her technical assistance.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors indicated no potential conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Goto, A., Hagiwara-Nagasawa, M., Kambayashi, R. et al. Reverse translational analysis of clinically reported, lamotrigine-induced cardiovascular adverse events using the halothane-anesthetized dogs. Heart Vessels 36, 424–429 (2021). https://doi.org/10.1007/s00380-020-01716-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00380-020-01716-8